270 related articles for article (PubMed ID: 10383513)
1. Efficacy of omeprazole versus ranitidine for symptomatic treatment of poorly responsive acid reflux disease-a prospective, controlled trial.
Maton PN; Orlando R; Joelsson B
Aliment Pharmacol Ther; 1999 Jun; 13(6):819-26. PubMed ID: 10383513
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group.
Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir DG; Gillon KR; Peacock RA; Fulton C
BMJ; 1999 Feb; 318(7182):502-7. PubMed ID: 10024259
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease.
Revicki DA; Sorensen S; Maton PN; Orlando RC
Dig Dis; 1998; 16(5):284-91. PubMed ID: 9892788
[TBL] [Abstract][Full Text] [Related]
4. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial.
Kahrilas PJ; Fennerty MB; Joelsson B
Am J Gastroenterol; 1999 Jan; 94(1):92-7. PubMed ID: 9934737
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
van Zyl J; van Rensburg C; Vieweg W; Fischer R
Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
Richter JE; Peura D; Benjamin SB; Joelsson B; Whipple J
Arch Intern Med; 2000 Jun; 160(12):1810-6. PubMed ID: 10871975
[TBL] [Abstract][Full Text] [Related]
7. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Richter JE; Campbell DR; Kahrilas PJ; Huang B; Fludas C
Arch Intern Med; 2000 Jun; 160(12):1803-9. PubMed ID: 10871974
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia.
Kaplan-Machlis B; Spiegler GE; Zodet MW; Revicki DA
Arch Fam Med; 2000 Jul; 9(7):624-30. PubMed ID: 10910310
[TBL] [Abstract][Full Text] [Related]
9. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease.
Revicki DA; Crawley JA; Zodet MW; Levine DS; Joelsson BO
Aliment Pharmacol Ther; 1999 Dec; 13(12):1621-30. PubMed ID: 10594397
[TBL] [Abstract][Full Text] [Related]
10. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease.
Richter JE; Sabesin SM; Kogut DG; Kerr RM; Wruble LD; Collen MJ
Am J Gastroenterol; 1996 Sep; 91(9):1766-72. PubMed ID: 8792695
[TBL] [Abstract][Full Text] [Related]
11. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Haag S; Holtmann G
Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
[TBL] [Abstract][Full Text] [Related]
12. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis.
Bate CM; Green JR; Axon AT; Murray FE; Tildesley G; Emmas CE; Taylor MD
Aliment Pharmacol Ther; 1997 Aug; 11(4):755-63. PubMed ID: 9305486
[TBL] [Abstract][Full Text] [Related]
13. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
Farley A; Wruble LD; Humphries TJ
Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
[TBL] [Abstract][Full Text] [Related]
14. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.
Venables TL; Newland RD; Patel AC; Hole J; Wilcock C; Turbitt ML
Scand J Gastroenterol; 1997 Oct; 32(10):965-73. PubMed ID: 9361167
[TBL] [Abstract][Full Text] [Related]
15. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists.
Lundell L; Backman L; Ekström P; Enander LH; Fausa O; Lind T; Lönroth H; Sandmark S; Sandzén B; Unge P
Aliment Pharmacol Ther; 1990 Apr; 4(2):145-55. PubMed ID: 1983321
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W
Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
[TBL] [Abstract][Full Text] [Related]
18. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
Festen HP; Schenk E; Tan G; Snel P; Nelis F
Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study.
van Zyl JH; de K Grundling H; van Rensburg CJ; Retief FJ; O'Keefe SJ; Theron I; Fischer R; Bethke T
Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):197-202. PubMed ID: 10741935
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease.
Stålhammar NO; Carlsson J; Peacock R; Müller-Lissner S; Bigard MA; Porro GB; Ponce J; Hosie J; Scott M; Weir DG; Fulton C; Gillon K; Bardhan KD
Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):483-97. PubMed ID: 10662395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
